POST Online Media Lite Edition



 

Shire sells cancer drugs to Servier for $2.4 billion

Staff Writer |
Shire is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion.

Article continues below




Shire said on Monday it would consider returning proceeds from the sale to shareholders through a buyback and that further selective disposals of non-strategic assets were possible.

Shire is a potential takeover target for Japan’s Takeda Pharmaceutical. Under UK takeover rules, Takeda has until April 25 to announce whether or not it will bid for Shire, which has a market value of around $47 billion.


What to read next

Servier: Fusafungine-containing medicines removed from market
Shire rejects buying proposal from AbbVie
Shire received better proposal from AbbVie